5: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney GG, Koller M, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin - Facklam M, Quinn JF, Isaacson SH, Jennings D, Omidvar O, Ellenbogen A. Results
from a Phase 1b multiple ascending - dose study of PRX002, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease.
5a: Jankovic J, Goodman I, Safirstein B, Schenk D, Kinney G, Koller M, Ness DK, Griffith S, Grundman M, Soto J, Ostrowitzki S, Boess F, Martin - Facklam M, Quinn J, Isaacson S, Jennings D, Omidvar O, Ellenbogen A. Results
From a Phase 1b multiple ascending - dose study of PRX002, an anti — alpha - synuclein monoclonal antibody, in patients with Parkinson's disease [abstract].
Not exact matches
The
phases of Corot
1b were detected by a team at Leiden Observatory in the Netherlands, who analysed changes in the amount of red light
from the system.
Ongoing
Phase 1b / 2 clinical trials combine entinostat with KEYTRUDA ®
from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ ®
from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO ®
from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Haplotype analyses were conducted using
PHASE software for SNPs
from the
1b receptor gene, TPH1 and TPH2.